- Home
- CKPT vs LNZA Comparison
CKPT vs LNZA Comparison
Compare CKPT & LNZA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CKPT
- LNZA
- Stock Information
- Founded
- CKPT 2014
- LNZA 2005
- Country
- CKPT United States
- LNZA United States
- Employees
- CKPT N/A
- LNZA N/A
- Industry
- CKPT Biotechnology: Pharmaceutical Preparations
- LNZA Major Chemicals
- Sector
- CKPT Health Care
- LNZA Industrials
- Exchange
- CKPT Nasdaq
- LNZA Nasdaq
- Market Cap
- CKPT 172.4M
- LNZA 199.8M
- IPO Year
- CKPT 2017
- LNZA N/A
- Fundamental
- Price
- CKPT $3.13
- LNZA $0.86
- Analyst Decision
- CKPT Strong Buy
- LNZA Strong Buy
- Analyst Count
- CKPT 3
- LNZA 3
- Target Price
- CKPT $12.00
- LNZA $4.33
- AVG Volume (30 Days)
- CKPT 753.4K
- LNZA 1.8M
- Earning Date
- CKPT 03-21-2025
- LNZA 03-17-2025
- Dividend Yield
- CKPT N/A
- LNZA N/A
- EPS Growth
- CKPT N/A
- LNZA N/A
- EPS
- CKPT N/A
- LNZA N/A
- Revenue
- CKPT $47,000.00
- LNZA $58,025,000.00
- Revenue This Year
- CKPT N/A
- LNZA $2.13
- Revenue Next Year
- CKPT $300,658.78
- LNZA $85.81
- P/E Ratio
- CKPT N/A
- LNZA N/A
- Revenue Growth
- CKPT N/A
- LNZA 7.99
- 52 Week Low
- CKPT $1.38
- LNZA $0.66
- 52 Week High
- CKPT $4.50
- LNZA $3.54
- Technical
- Relative Strength Index (RSI)
- CKPT 46.36
- LNZA 43.62
- Support Level
- CKPT $3.10
- LNZA $0.66
- Resistance Level
- CKPT $3.43
- LNZA $1.07
- Average True Range (ATR)
- CKPT 0.26
- LNZA 0.12
- MACD
- CKPT 0.00
- LNZA 0.03
- Stochastic Oscillator
- CKPT 33.03
- LNZA 49.02
About CKPT Checkpoint Therapeutics Inc.
Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the USA. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR-related protein (GITR) and carbonic anhydrase IX (CAIX). The company is evaluating its lead small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor ("EGFR") inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.
About LNZA LanzaTech Global Inc.
LanzaTech Global Inc is a nature-based carbon refining company that transforms waste carbon into the chemical building blocks for consumer goods such as sustainable fuels, fabrics, and packaging that people use in their daily lives. The company's goal is to reduce the need for virgin fossil fuels by challenging and striving to change the way the world uses carbon.